ARCELLX, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.19 USD | -1.04% |
|
-1.78% | -4.43% |
| 14/06 | Arcellx Insider Sold Shares Worth $1,102,668, According to a Recent SEC Filing | MT |
| 31/05 | Piper Sandler Starts Arcellx With Overweight Rating, $70 Price Target | MT |
Presenter SpeechJason Gerberry (Analysts)[Audio Gap]
Bank of Ameri...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Companyâs lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
Calendar
12/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
53.75
USD
Average target price
79.93
USD
Spread / Average Target
+48.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.43% | 287.58Cr | |
| +34.95% | 5.28TCr | |
| -7.32% | 3.89TCr | |
| +35.51% | 3.82TCr | |
| -10.77% | 2.68TCr | |
| +11.96% | 2.62TCr | |
| -18.05% | 1.99TCr | |
| +36.29% | 1.32TCr | |
| +29.36% | 1.22TCr | |
| -2.62% | 1.18TCr |
- Stock Market
- Equities
- ACLX Stock
- News Arcellx, Inc.
- Transcript : Arcellx, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03
